AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported Thursday that its earnings per diluted share in fiscal 2025 fell to NZ$0.11 from NZ$0.15 a year earlier.
Revenue for the year ended March 31 was NZ$208 million, up from NZ$195.4 million in the same period a year earlier.
The company expects fiscal 2026 operating profit in the range of NZ$20 million to NZ$24 million.
The board declared a final dividend of NZ$0.018 per share, up from NZ$0.016 a year earlier, payable on July 4 to shareholders on record as of June 20.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。